|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
9770
|
DOTA-TATE acetate
|
9770.0001: 1 mg per vial
9770.0010: 10 mg per vial
Please inquire for customized
filling and bulk quantities.
|
|
|
Precursor for radiolabelled DOTA-[Tyr3]octreotate
|
|
|
|
|
|
|
|
|
Molar Mass: 1435.63
|
|
|
C65H90N14O19S2
|
|
|
[177943-89-4]
|
|
|
|
|
|
Colourless to off-white freeze-dried solid packaged in dark glass screw cap vials.
|
|
|
|
|
|
|
|
|
Purity: ≥ 97 %
|
|
|
Certificates:
CoA; MS (identity) and HPLC (purity)
|
|
|
Chemical Name:
CA index name: CN L-Threonine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2→7)-disulfide, acetate (salt)
|
|
|
Synonymes:
DOTA-[Tyr3]-Octreotate, DOTA-[Tyr3, Thr8]-Octreotide
|
|
|
Literature:
1. De Jong M. et al.: Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs. J. Nucl. Med., 2005, 46,13S
|
|
|
2. Valkema R. et al. Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0,Tyr3-Octreotate. J. Nucl. Med. 2005, 46, 83S
|
|
|
|
|
|
|
|
|
|
|
|
date of product catalogue issue:
05 April 2012
|